newsfilter
← Latest News
GlobeNewswire·

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make